Patent application number | Description | Published |
20100261730 | ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME - The invention relates to alkynylaryl compounds according to the general formula (I) in which A, B, D, E, R | 10-14-2010 |
20120328610 | TRIAZOLOPYRIDINES - The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R | 12-27-2012 |
20120328611 | SUBSTITUTED TRIAZOLOPYRIDINES - The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors: Formula (I), in which R | 12-27-2012 |
20130131055 | FUROPYRIDINYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF - This invention relates to novel 4-(furo[3,2-c]pyridin-2-yl)-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders. | 05-23-2013 |
20130156756 | Substituted Triazolopyridines - The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R | 06-20-2013 |
20140113901 | IMIDAZOPYRIDAZINES AS AKT KINASE INHIBITORS - Imidazopyridazines of formula (I) a process for their production and the use thereof. | 04-24-2014 |
20140120087 | TRIAZOLOPYRIDINES - The present invention relates to triazolopyridine compounds of general formula (I): in which R | 05-01-2014 |
20140249133 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES - Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. | 09-04-2014 |
20140315934 | SUBSTITUTED BENZYLPYRAZOLES - Compounds of formula (I) and their use as pharmaceutical. | 10-23-2014 |